World Pharma News

MHRA updates Dysport license to include upper limb spasticity in children

By Anna Smith The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted Ipsen a licence update for Dysport (abobotulinumtoxinA), extending the use of the drug to focal spasticity of upper limbs in paediatric cerebral palsy (CP) patients, two…
07 Ιανουαρίου, 2020
World Pharma News

In recent years, the industry has seen clinical trials increase in complexity but decline in...

AstraZeneca today announced positive results from the landmark Phase III DAPA-HF trial which showed...

5 - 7 November 2019, Frankfurt, Germany. CPhI Worldwide - the world's largest pharma event...

by Nicole Ntampou

By €8.5 billion each year the German economy can potentially reduce...

 

Labour's newly announced policy on research...

An interview to Nikoleta Dambou

Other than the cost of a drug, should we consider other parameters...

Prescription and illegal opioids are commonly abused because they are so...